Combined with our recent study in TNBCs (Qadir et al., 2021), this work highlights a complex picture: although CD95 loss in tumor cells in TNBC patients can curtail the anti-tumor activity of CD95L-expressing T- and NK cells, it also induces an inflammatory signature, resulting in a more pronounced NK-mediated anti-tumor response (Qadir et al., 2021). Here, FASLG is linked to neoplasm.